Supersaturation of VEP in Migraine Without Aura Patients Treated with Topiramate: An Anatomo-Functional Biomarker of the Disease

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Mar 6

PMID 33671875

Citations 6

Authors

Ciro De Luca

Sara Gori

Sonia Mazzucchi

Elisa Dini

Martina Cafalli

Gabriele Siciliano

Michele Papa

Filippo Baldacci

Affiliations

Soon will be listed here.

Abstract

Migraine is a primary headache with high prevalence among the general population, characterized by functional hypersensitivity to both exogenous and endogenous stimuli particularly affecting the nociceptive system. The hyperresponsivity of cortical neurons could be due to a disequilibrium in the excitatory/inhibitory signaling. This study aimed to investigate the anatomo-functional pathway from the retina to the primary visual cortex using visual evoked potentials (VEP). Contrast gain protocol was used in 15 patients diagnosed with migraine without aura (at baseline and after 3 months of topiramate therapy) and 13 controls. A saturation (S) index was assessed to monitor the response of VEP's amplitude to contrast gain. Non-linear nor monotone growth of VEP (S < 0.95) was defined as supersaturation. A greater percentage of migraine patients (53%) relative to controls (7%) showed this characteristic. A strong inverse correlation was found between the S index and the number of days separating the registration of VEP from the next migraine attack. Moreover, allodynia measured through the Allodynia Symptoms Check-list (ASC-12) correlates with the S index both at baseline and after 3 months of topiramate treatment. Other clinical characteristics were not related to supersaturation. Topiramate therapy, although effective, did not influence electrophysiological parameters suggesting a non-intracortical nor retinal origin of the supersaturation (with possible involvement of relay cells from the lateral geniculate nucleus). In conclusion, the elaboration of visual stimuli and visual cortex activity is different in migraine patients compared to controls. More data are necessary to confirm the potential use of the S index as a biomarker for the migraine cycle (association with the pain-phase) and cortical sensitization (allodynia).

Citing Articles

Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients.

Della Vecchia A, De Luca C, Becattini L, Curto L, Ferrari E, Siciliano G Biomedicines. 2024; 12(3).

PMID: 38540290 PMC: 10968025. DOI: 10.3390/biomedicines12030677.

Prospective Matched Case-Control Study of Over-Early P100 Wave Latency in Migraine with Aura.

AlShamrani F, AlSheikh M, Almuslim N, Azman H, Alkhamis F, Nazish S Biomedicines. 2023; 11(11).

PMID: 38001979 PMC: 10669729. DOI: 10.3390/biomedicines11112979.

Use of Visual Electrophysiology to Monitor Retinal and Optic Nerve Toxicity.

Chiang T, White K, Kurup S, Yu M Biomolecules. 2022; 12(10).

PMID: 36291599 PMC: 9599231. DOI: 10.3390/biom12101390.

Dissecting Migraine: The Future of Anatomical, Functional, and Liquid Biomarkers.

De Luca C, Baldacci F J Clin Med. 2022; 11(19).

PMID: 36233402 PMC: 9571522. DOI: 10.3390/jcm11195538.

The Spatiotemporal Coupling: Regional Energy Failure and Aberrant Proteins in Neurodegenerative Diseases.

Virtuoso A, Colangelo A, Maggio N, Fennig U, Weinberg N, Papa M Int J Mol Sci. 2021; 22(21).

PMID: 34768733 PMC: 8583302. DOI: 10.3390/ijms222111304.

References

. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

Tsai J, Norcia A, Ales J, Wade A . Contrast gain control abnormalities in idiopathic generalized epilepsy. Ann Neurol. 2011; 70(4):574-82. PMC: 3183388. DOI: 10.1002/ana.22462. View

De Logu F, Landini L, Janal M, Li Puma S, De Cesaris F, Geppetti P . Migraine-provoking substances evoke periorbital allodynia in mice. J Headache Pain. 2019; 20(1):18. PMC: 6734434. DOI: 10.1186/s10194-019-0968-1. View

Coppola G, Di Renzo A, Tinelli E, Di Lorenzo C, Di Lorenzo G, Parisi V . Thalamo-cortical network activity during spontaneous migraine attacks. Neurology. 2016; 87(20):2154-2160. DOI: 10.1212/WNL.0000000000003327. View

Bassez I, Van de Steen F, Ricci K, Vecchio E, Gentile E, Marinazzo D . Dynamic Causal Modelling of the Reduced Habituation to Painful Stimuli in Migraine: An EEG Study. Brain Sci. 2020; 10(10). PMC: 7601741. DOI: 10.3390/brainsci10100712. View

Kjellstrom S, Bruun A, Isaksson B, Eriksson T, Andreasson S, Ponjavic V . Retinal function and histopathology in rabbits treated with Topiramate. Doc Ophthalmol. 2006; 113(3):179-86. DOI: 10.1007/s10633-006-9027-8. View

Coppola G, Pierelli F, Schoenen J . Habituation and migraine. Neurobiol Learn Mem. 2008; 92(2):249-59. DOI: 10.1016/j.nlm.2008.07.006. View

Nguyen B, McKendrick A, Vingrys A . Abnormal inhibition-excitation imbalance in migraine. Cephalalgia. 2015; 36(1):5-14. DOI: 10.1177/0333102415576725. View

De Luca C, Colangelo A, Virtuoso A, Alberghina L, Papa M . Neurons, Glia, Extracellular Matrix and Neurovascular Unit: A Systems Biology Approach to the Complexity of Synaptic Plasticity in Health and Disease. Int J Mol Sci. 2020; 21(4). PMC: 7073232. DOI: 10.3390/ijms21041539. View

10.

Lisicki M, DOstilio K, Coppola G, Nonis R, de Noordhout A, Parisi V . Headache Related Alterations of Visual Processing in Migraine Patients. J Pain. 2019; 21(5-6):593-602. DOI: 10.1016/j.jpain.2019.08.017. View

11.

Wang M, Li Y, Lin Y . GABAA receptor α2 subtype activation suppresses retinal spreading depression. Neuroscience. 2015; 298:137-44. DOI: 10.1016/j.neuroscience.2015.04.016. View

12.

Petta F, De Luca C, Triggiani M, Casolaro V . Fragments of truth: T-cell targets of polyclonal immunoglobulins in autoimmune diseases. Curr Opin Pharmacol. 2014; 17:1-11. DOI: 10.1016/j.coph.2014.05.002. View

13.

Giorgio A, Lupi C, Zhang J, De Cesaris F, Alessandri M, Mortilla M . Changes in grey matter volume and functional connectivity in cluster headache versus migraine. Brain Imaging Behav. 2019; 14(2):496-504. DOI: 10.1007/s11682-019-00046-2. View

14.

de Tommaso M, Sciruicchio V, Bellotti R, Castellano M, Tota P, Guido M . Discrimination between migraine patients and normal subjects based on steady state visual evoked potentials: discriminant analysis and artificial neural network classifiers. Funct Neurol. 1998; 12(6):333-8. View

15.

Ziemann U . Pharmacology of TMS. Suppl Clin Neurophysiol. 2003; 56:226-31. View

16.

Dini E, Mazzucchi S, De Luca C, Cafalli M, Chico L, Gerfo A . Plasma Levels of Oxidative Stress Markers, before and after Treatment, in Chronic Migraine. Toxins (Basel). 2019; 11(10). PMC: 6832499. DOI: 10.3390/toxins11100608. View

17.

Pomes L, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P . Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019; 20(1):56. PMC: 6734220. DOI: 10.1186/s10194-019-1010-3. View

18.

Coppola G, Parisi V, Di Lorenzo C, Serrao M, Magis D, Schoenen J . Lateral inhibition in visual cortex of migraine patients between attacks. J Headache Pain. 2013; 14:20. PMC: 3620512. DOI: 10.1186/1129-2377-14-20. View

19.

Cortese F, Coppola G, Di Lenola D, Serrao M, Di Lorenzo C, Parisi V . Excitability of the motor cortex in patients with migraine changes with the time elapsed from the last attack. J Headache Pain. 2017; 18(1):2. PMC: 5218956. DOI: 10.1186/s10194-016-0712-z. View

20.

Sand T, Zhitniy N, White L, Stovner L . Visual evoked potential latency, amplitude and habituation in migraine: a longitudinal study. Clin Neurophysiol. 2008; 119(5):1020-7. DOI: 10.1016/j.clinph.2008.01.009. View